Iterum Therapeutics Reports Third Quarter 2024 Financial Results
14. November 2024 07:00 ET
|
Iterum Therapeutics PLC
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
11. November 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
25. Oktober 2024 11:03 ET
|
Iterum Therapeutics PLC
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th...
Iterum Therapeutics to Present Data at IDWeek 2024
10. Oktober 2024 08:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
09. Oktober 2024 17:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics...
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
10. September 2024 07:00 ET
|
Iterum Therapeutics PLC
FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
06. September 2024 16:30 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral...
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
14. August 2024 07:00 ET
|
Iterum Therapeutics PLC
-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call...
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
07. August 2024 16:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Expiration and Results of Rights Offering
06. August 2024 17:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...